Petar Todorov

Petar Todorov

Auto-generated profile, based on publicly available information

Petar Todorov

Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SRSteve Rodriguez
Steve Rodriguez
CHClemens Hug
Clemens Hug
PTPetar Todorov
Petar Todorov
NMNienke Moret
Nienke Moret
SBSarah A. Boswell
Sarah A. Boswell
ASArtem Sokolov
Artem Sokolov
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. We present DRIAD (Drug Repurposing In AD), a machine learning framework that quantifies potential associations between the pathology of AD severity (the Braak stage) and molecular mechanisms as encoded in lists of gene names. DRIAD is applied to lists of genes arising from perturbations in differentiated human neural cell cultures by 80 FDA-approved and clinically tested drugs, producing a ranked list of possible repurposing candidates. Top-scoring drugs are inspected for common trends among their targets. We propose that the DRIAD method can be used to nominate drugs that, after additional validation and identification of relevant pharmacodynamic biomarker(s), could be readily evaluated in a clinical trial.

23 August 2021 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
JMJordi Merino
Jordi Merino
HDHassan S. Dashti
Hassan S. Dashti
CSChloe Sarnowski
Chloe Sarnowski
JLJacqueline M. Lane
Jacqueline M. Lane
PTPetar V. Todorov
Petar V. Todorov
RSRicha Saxena
Richa Saxena

27 June 2021 in Diabetes
Verified
Journal Article
Open access
PDF file
MLMette Q. Ludwig
Mette Q. Ludwig
PTPetar V. Todorov
Petar V. Todorov
KEKristoffer L. Egerod
Kristoffer L. Egerod
DODavid P. Olson
David P. Olson
TPTune H. Pers
Tune H. Pers
The dorsal vagal complex (DVC) in the hindbrain, composed of the area postrema, nucleus of the solitary tract, and dorsal motor nucleus of the vagus, plays a critical role in modulating satiety. The incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) act directly in the brain to modulate feeding, and receptors for both are expressed in the DVC. Given the impressive clinical responses to pharmacologic manipulation of incretin signaling, understanding the central mechanisms by which incretins alter metabolism and energy balance is of critical importance. Here, we review recent single-cell approaches used to detect molecular signatures of GLP-1 and GIP receptor–expressing cells in the DVC. In addition, we discuss how current advancements in single-cell transcriptomics, epigenetics, spatial transcriptomics, and circuit mapping techniques have the potential to further characterize incretin receptor circuits in the hindbrain.

1 May 2019 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
SRSusanne Ramm
Susanne Ramm
PTPetar Todorov
Petar Todorov
VCVidya Chandrasekaran
Vidya Chandrasekaran
ADAnders Dohlman
Anders Dohlman
MMMaria B Monteiro
Maria B Monteiro
VVVishal S Vaidya
Vishal S Vaidya
The failure to predict kidney toxicity of new chemical entities early in the development process before they reach humans remains a critical issue. Here, we used primary human kidney cells and applied a systems biology approach that combines multidimensional datasets and machine learning to identify biomarkers that not only predict nephrotoxic compounds but also provide hints toward their mechanism of toxicity. Gene expression and high-content imaging-derived phenotypical data from 46 diverse kidney toxicants were analyzed using Random Forest machine learning. Imaging features capturing changes in cell morphology and nucleus texture along with mRNA levels of HMOX1 and SQSTM1 were identified as the most powerful predictors of toxicity. These biomarkers were validated by their ability to accurately predict kidney toxicity of four out of six candidate therapeutics that exhibited toxicity only in late stage preclinical/clinical studies. Network analysis of similarities in toxic phenotypes was performed based on live-cell high-content image analysis at seven time points. Using compounds with known mechanism as reference, we could infer potential mechanisms of toxicity of candidate therapeutics. In summary, we report an approach to generate a multidimensional biomarker panel for mechanistic de-risking and prediction of kidney toxicity in in vitro for new therapeutic candidates and chemical entities.

15 June 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
DGDanielle M. Greenawalt
Danielle M. Greenawalt
WLWinnie S. Liang
Winnie S. Liang
SSSakina Saif
Sakina Saif
JJJustin Johnson
Justin Johnson
PTPetar Todorov
Petar Todorov
KBKate Byth
Kate Byth
Current understanding of the mutation spectrum of relapsed/refractory (RR) tumors is limited. We performed whole exome sequencing (WES) on 47 diffuse large B cell lymphoma (DLBCL) tumors that persisted after R-CHOP treatment, 8 matched to primary biopsies. We compared genomic alterations from the RR cohort against two treatment-naïve DLBCL cohorts (n=112). While the overall number and types of mutations did not differ significantly, we identified frequency changes in DLBCL driver genes. The overall frequency of MYD88 mutant samples increased (12% to 19%), but we noted a decrease in p.L265P (8% to 4%) and increase in p.S219C mutations (2% to 6%). CARD11 p.D230N, PIM1 p.K115N and CD79B p.Y196C mutations were not observed in the RR cohort, although these mutations were prominent in the primary DLBCL samples. We observed an increase in BCL2 mutations (21% to 38% of samples), BCL2 amplifications (3% to 6% of samples) and CREBBP mutations (31% to 42% of samples) in the RR cohort, supported by acquisition of mutations in these genes in relapsed compared to diagnostic biopsies from the same patient. These increases may reflect the genetic characteristics of R-CHOP RR tumors expected to be enriched for during clinical trial enrollment. These findings hold significance for a number of emerging targeted therapies aligned to genetic targets and biomarkers in DLBCL, reinforcing the importance of time-of-treatment biomarker screening during DLBCL therapy selection.

9 May 2019 in Bioinformatics
Verified
Journal Article
Open access
PTPetar V Todorov
Petar V Todorov
BGBenjamin M Gyori
Benjamin M Gyori
JBJohn A Bachman
John A Bachman
PSPeter K Sorger
Peter K Sorger
Summary: INDRA-IPM (Interactive Pathway Map) is a web-based pathway map modeling tool that combines natural language processing with automated model assembly and visualization. INDRA-IPM contextualizes models with expression data and exports them to standard formats. Availability and implementation: INDRA-IPM is available at: http://pathwaymap.indra.bio. Source code is available at http://github.com/sorgerlab/indra_pathway_map. The underlying web service API is available at http://api.indra.bio:8000. Supplementary information: Supplementary data are available at Bioinformatics online.